OBJECTIVE OF THE PRESENT WORK

- Prior art search for the proposed research work revealed that Marketing approval can be obtained for the product as there is no Capsule dosage form & there are no patents on such dosage forms present in market for Tianeptine sodium.
- Tianeptine sodium is available as tablet 12.5 mg (STABLON) dosage form in market; yet non infringement opinion for the same is to be prepared in order to achieve all possible non infringing products as Tianeptine Capsules.
- As the capsule shell act as a Primary packaging material & as protective covering, it helps the formulation to be stable for long term as our API is very hygroscopic in nature & required “to be protected from moisture”, it is to be needed to encapsulate it, Thus it is easily formulated in the production process & help the manufacturer. Also it has commercializing and industrially applicability. (European Pharmacopoeia Commission, 2005)
- Tianeptine capsules is useful for the Disease in Depression as antidepressant Drug for Old person & children who are unable to take tablets or nauseous for its bitter nature.
- The dosage form Capsule is devoid of step Disintegration, as there are granules which are to be dissolved only after administering from the oral cavity.
- Tianeptine capsule have often being assumed to have better bioavailability than Tablets. Most likely this assumption derives from the fact the gelatin shell rapidly dissolves & ruptures which afford at least the potential for rapid release of drugs & easily formulated as tablets, thus help the human in disease condition in depression to provide prompt release of it.
- Thus a Tianeptine capsule 12.5 mg dosage form, as the formulation as an innovative step with commercializing and industrially applicability, can be prepared with serve as better option compared to already existing product in the market.